Keywords: zeneca, fast-tracks, zd4522, superstatin, completed, phase, ii
Zeneca fast-tracks ZD4522 "superstatin"
Article | 15 February 1999
Zeneca has completed Phase II trials of its new-generation HMG-CoAreductase inhibitor ZD4522 and has initiated an accelerated Phase III program ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
